Navigation Links
Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
Date:6/18/2009

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Florida corporation, announce the signature of an exclusive license agreement for the development and commercialization of Debio 0928, a small molecule in early preclinical development that inhibits the protein-protein interaction between Raf-1 (key signalling kinase in the MAP kinase pathway) and Rb (retinoblastoma protein). Rb acts as a barrier to cell division and proliferation. However, when Raf-1 physically interacts with Rb, it triggers a cascade of signals that eventually overcomes this barrier, thus inducing cellular proliferation. By preventing the interaction between Raf-1 and Rb and blocking the cell cycle, Debio 0928 creates a new strategy in the fight against cancer and is thus a potentially promising novel anti-tumour drug.

Under the terms of the agreement, Debiopharm shall pay Moffitt an up-front fee, as well as predefined advanced milestone payments during the development of Debio 0928. First entry of the product into man is expected for 2012.

"This discovery, made by the collaboration between Drs. Srikumar Chellappan, Said Sebti, and Nicholas Lawrence at Moffitt, is a novel approach to the treatment of cancer," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "Being able to de-activate a key signalling kinase like Raf-1, known to be involved in many types of cancer, could open the door to more effective oncology treatments in the future."

"The disruption of the binding of the tumour promoter Raf-1 to the tumour suppressor Rb with Debio 0928 is a novel, first-in-class therapeutic strategy that has the potential for targeting a wide spectrum of human cancers," added Dr. Said Sebti, Chair, Department of Drug Discovery at Moffitt.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center [http://www.moffitt.org/] is an NCI [http://www.cancer.gov/] Comprehensive Cancer Center - a designation that recognises Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network [http://www.nccn.org/index.asp], a prestigious alliance of the country's leading cancer centres, and is listed in U.S. News & World Report [http://health.usnews.com/sections/health/best-hospitals] as one of "America's Best Hospitals" for cancer. Moffitt's sole mission is to contribute to the prevention and cure of cancer.

For more information on Moffitt Cancer Center, please visit: http://www.moffitt.org .

    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41-(0)21-321-01-11
    Fax:  +41-(0)21-321-01-69
    mwagner@debiopharm.com

    Moffitt Contact
    Michelle Foley
    Manager, Community Relations & Public Affairs
    Tel: +1-813-745-1505
    Fax: +1-813-745-1380
    michelle.foley@moffitt.org

    Additional Media Contacts
    In London
    Maitland
    Brian Hudspith
    Tel: +44-(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
5. Debiopharm and EPFL Establish an Oncology Chair
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
8. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
9. Digital Healthcare Specialist Cadient Group Ranked #2 on List of Full-service Advertising Agencies in the Philadelphia Region
10. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
11. Cadient Group Brings Home the Gold and Two Bronze Aster Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):